Compare Merck & Co., Inc. (MRK) vs SP Funds S&P 500 Sharia Industry Exclusions ETF (SPUS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs SP Funds S&P 500 Sharia Industry Exclusions ETF — how do they compare? Merck & Co., Inc. trades at $125.97 (market cap $307.25B), while SP Funds S&P 500 Sharia Industry Exclusions ETF trades at $57.02. The key difference: Merck & Co., Inc. pays a 2.73% dividend while SP Funds S&P 500 Sharia Industry Exclusions ETF pays none, and Merck & Co., Inc. is trading nearer its 52-week high, SP Funds S&P 500 Sharia Industry Exclusions ETF nearer its low. Which is the better fit depends on your goals.
| MRK | SPUS | |
|---|---|---|
Market Cap | $307.25B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $129.52 | $59.51 |
52-Week Low | $77.60 | $45.32 |
Enterprise Value | $350.66B | — |
Dividend Yield | 2.73% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $126.27, down 0.96% on the day, with a neutral technical signal and strong fundamental performance. The company reported robust 2025 results with $65.01B revenue and $18.25B net income, beating EPS estimates in recent quarters. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, while analyst consensus remains bullish with a $137.30 price target.
Outlook is positive driven by earnings momentum and strategic M&A, but risks include patent expirations and competitive pressures. The stock offers a dividend yield with upcoming payment, supporting income investors. Valuation multiples are elevated, requiring sustained growth to justify current levels amid macroeconomic uncertainties.
SPUS trades at $57.07, up 1.1% today, with a bearish technical signal from moving averages. The stock exhibits a consistent dividend payout pattern, with recent quarterly dividends of $0.03. Support and resistance levels suggest near-term price consolidation. Financial ratios are not available in the provided data.
The outlook for SPUS is mixed, with technical weakness offset by dividend stability. Risks include broader market volatility and reliance on dividend strategies. Upside potential hinges on sustained profitability and positive earnings momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About SP Funds S&P 500 Sharia Industry Exclusions ETF
SPUS tracks a market-cap weighted index of S&P 500 stocks that adhere to Sharia law. It screens out companies involved in non-compliant business activities such as alcohol, tobacco, gambling, and conventional finance, as well as excluding sectors like Aerospace & Defense, and Data Processing. By focusing on low-leverage stocks, SPUS provides investors with a value-conscious, ethically-aligned exposure to a diversified portfolio of large-cap U.S. equities.
Read more on SPUS →
